Close mobile menu×
Close mobile menu

Julia J. Wattacheril, MD, MPH

Board Certifications: 
Transplant Hepatology, Gastroenterology
Expertise in: 
Internal Medicine
Accepting New Patients
Virtual Visits/Telehealth
Profile Headshot

Schedule an Appointment

Virtual Visits/Telehealth

Virtual Visits allow you to connect with your provider from the comfort, convenience, and safety of your own home.

Schedule Virtual Visit

Phone Appointments

New and Existing Patients:

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Connect Sign In

Credentials & Experience

Board Certifications

  • Transplant Hepatology
  • Gastroenterology

Clinical Expertise

  • Chronic Liver Disease
  • Hereditary Liver Disease
  • Liver Disease
  • Liver Transplantation
  • Non-Alcoholic Fatty Liver Disease
  • Non-Alcoholic Steatohepatitis

Education & Training

  • 2004 Baylor College of Medicine
  • Residency: Baylor Hospital
  • Fellowship: Vanderbilt University Medical Center
  • Fellowship: 2011 NewYork-Presbyterian Hospital/Columbia University Medical Center

Honors & Awards

  • 2003 Alpha Omega Alpha
  • 2000 Glasgow-Rubin Achievement Citation recipient, American Medical Women’s Association

About Julia Wattacheril

Dr. Wattacheril's clinical specialties include all aspects of transplant hepatology, general hepatology and gastroenterology with emphasis on metabolic liver disease and obesity. She specializes in nonalcoholic fatty liver disease as well as all forms of hepatitis, chronic liver disease, and liver cancer in addition to liver transplantation. Her research interests include hepatic steatosis, insulin resistance, gut hormones and metabolic liver disease in adults. Her current research concentrates on the relationship between proteins and lipids that differentiate steatosis from steatohepatitis using an integrated omics approach.

Academic Titles

  • Associate Professor of Medicine at CUMC

Administrative Positions

  • Director of the Nonalcoholic Fatty Liver Disease Program
  • Attending, New York - Presbyterian Hospital

Committee/Societies/Council Memberships

  • Liver Forum, academic investigator
  • Noninvasive Biomarkers of Metabolic Liver Disease (NIMBLE) consortium, academic investigator
  • New York Genome Center, affiliate member
  • American Liver Foundation, NY chapter, Medical Advisory Committee member
  • Institute for Genomic Medicine, member
  • New York Academy of Sciences, member
  • Texas Medical Association, member
  • American Association for the Study of Liver Diseases, member
  • American Liver Foundation, Medical Advisory Committee,member
  • American Board of Internal Medicine, member
  • American Gastroenterological Association, member
  • American Society of Human Genetics, member
  • European Society of Human Genetics, member
  • National Valedictorian Society, member

Hospital Affiliations

  • NewYork-Presbyterian / Columbia University Irving Medical Center
  • NewYork-Presbyterian / Weill Cornell Medical Center

Languages

  • Spanish

Gender

  • Female

Insurance Accepted

Aetna

  • Aetna Signature Administrators
  • EPO
  • HMO
  • Medicare Managed Care
  • NYP Employee Plan
  • NY Signature
  • POS
  • PPO
  • Student Health

Affinity Health Plan

  • Essential Plan
  • Medicaid Managed Care

AgeWell

  • Medicare Managed Care
  • Special Needs

Amida Care

  • Special Needs

Capital District Physician Health Plan

  • Capital District Physician Health Plan

Cigna

  • EPO
  • Great West (National)
  • HMO
  • POS
  • PPO

Elderplan

  • Medicare Managed Care

Emblem/GHI

  • Medicare Managed Care
  • PPO

Empire Blue Cross/Blue Shield

  • EPO
  • Medicare Managed Care
  • PPO

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Health First

  • Child/Family Health Plus
  • Leaf (Exchange)
  • Medicaid Managed Care
  • Medicare Managed Care

Health Insurance Plan of NY (HIP)

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Health Plus - Amerigroup

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Local 1199

  • Local 1199

MagnaCare (National)

  • MagnaCare

Medicare

  • Traditional Medicare

Multiplan

  • Multiplan

MVP Health Care

  • Child/Family Health Plus
  • Essential Plan
  • HMO
  • Medicaid Managed Care

Oxford Health Plans

  • Freedom
  • Liberty

United Health Care

  • Columbia Employee POS
  • Compass (Exchange)
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE SelectHealth

  • Medicare Managed Care
  • Select Health
  • Special Needs

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
622 West 168th Street
PH, Floor 14
New York, New York 10032
Primary
2
622 West 168th Street
PH, Floor 14
New York, New York 10032
Primary

Research

Dr. Wattacheril is an Associate Professor of Medicine and Director of the Nonalcoholic Fatty Liver Disease (NAFLD) Program in the Center for Liver Disease and Transplantation. Her primary Translational science interests include: 1) investigating the relationship between lipids and proteins within the context of the development and progression of nonalcoholic steatohepatitis, 2) optimizing the clinical care of patients with NAFLD pre and post-transplantation, 3) understanding the relationship between NAFLD and hepatocellular carcinoma and 4) enhancing the care of liver disease patients using genomics and electronic health record phenotyping. She mentors several residents and gastroenterology fellows in addition to computational geneticists, nurse practitioners, dietitians, and anyone interested in enhancing the integrated knowledge and care for patients with chronic liver disease.

Research Interests

  • Algorithm development and machine learning methods for disease phenotyping
  • Body Composition
  • Hepatocellular carcinoma
  • Insulin Resistance
  • Lipid metabolism
  • Metabolic liver diseases
  • Non-alcoholic fatty liver disease (including non-alcoholic steatohepatitis)
  • OMICs
  • Transplant hepatology

Selected Publications

ORIGINAL, PEER-REVIEWED RESEARCH PUBLICATIONS

  1. *Pomenti S, Gandle C, Abu Sbeih H, Phipps M, Livanos A, Guo A, Yeh J, Burney H, Liu H, Dakhoul L, Kettler C, Gawrieh S, deLemos A, Scanga A, Chalasani N, Miller E, Wattacheril J. Hepatocellular Carcinoma in Hispanic Patients: Trends and Outcomes in a Large United States Cohort. Hep Communications2020: doi.org/10.1002/hep4.1575
  2. *Phipps M, Livanos A, Guo A, Pomenti S, Yeh J, Dakhoul L, Burney H, Kettler C, Liu H, Miller E, GawriehS, deLemos A, Scanga A, Chalasani N, Wattacheril J. Gender Matters: Characteristics of Hepatocellular Carcinoma in Women from a Large, Multicenter Study in the United States. Am J Gastroenterol2020: doi: 10.14309/ajg.0000000000000643.
  3. deLemos, A, Patel M, Gawrieh S, Burney H, Dakhoul L, Miller E, Scanga A, Kettler C, Liu H, Roche P, Wattacheril J, Chalasani N. Distinctive Features and Outcomes of Hepatocellular Carcinoma in Patients with Alcohol-Related Liver Disease: A US Multicenter Study. Clin Transl Gastroenterol2020: doi: 10.14309/ctg.0000000000000139.
  4. Siddiqui MS, Van Natta ML, Connelly MA, Vuppalanchi R, Neuschwander-Tetri BA, Tonascia J, Guy C, Loomba R, Dasarathy S, Wattacheril J,Chalasani N, Sanyal AJ; NASH-CRN. Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis. J Hepatology2020 doi: 10/1016/j.hep.2019.10.006
  5. *Gawrieh S, Dakhoul L, Miller E, Scanga A, deLemos A, Kettler C, Burney H, Liu H, Abu-Sbeih H, Chalasani N, Wattacheril J.Characteristics, Aetiologies and Trends of Hepatocellular Carcinoma in Patients without Cirrhosis: A United States Multicenter Study. Alimentary Pharmacology and Therapeutics.2019 doi.org/10.1111/apt15464
  6. Wattacheril J, Shea PR, Mohammad S, Behlin C, Aggarwal V, Wilson LA, Yates KP, Ito J, Fishbein M, Stong N, Lavine JE, Goldstein DB. Exome sequencing of an adolescent with nonalcoholic fatty liver disease identifies a clinically actionable case of Wilson Disease. Cold Spring Harb Mol Case Stud.2018 Oct 1.doi: 0.1101/mcs.a003087
  7. Wattacheril J, Lavine JE, Chalasani NP, Guo X, Kwon S, Schwimmer J, Molleston JP, Loomba R, Brunt EM, Chen YI, Goodarzi MO, Taylor KD, Yates KP, Tonascia J, Rotter JI. Genome Wide Associations Related to Hepatic Histology in Nonalcoholic Fatty Liver Disease in Hispanic Boys. J Pediatr. 2017 Nov. doi:10.1016/j.jpeds.2017.08.004
  8. WattacherilJ,Rose,K.L.,Hill,S.,Lanciault,C.,Murray,C.R.,Washington,K.,Williams,B.,English,W.,Spann,M.,Clements,R.,Abumrad,N., andFlynn,C.R.(2017)NAFLDPhosphoproteomics:AFunctionalPieceofthePrecisionPuzzle.HepatolRes, doi:10.1111/hepr.12885.
  9. CoreyKE,GawriehS,deLemosAS,ZhengH,ScangaAE,HaglundJW,SanchezJ,DanfordCJ,ComerfordM,BossiK,MunirS,ChalasaniN,WattacherilJ.Risk factors for hepatocellular carcinoma in cirrhosis due to nonalcoholic fatty liver disease: A multicenter, case-control study. World J Hepatol2017; 9(7): 385-390
  10. Guo Y, Xiong Y, Sheng Q, Zhao S,Wattacheril J, Flynn CR. A micro-RNA expression signature for human NAFLD progression. J Gastroenterol. 2016 Feb 13.
  11. Garcia A, Kasim N, Gonzalez, R, Antoun J, Eckert E, Marks P, Wattacheril J, Abumrad N, Tamboli R, Walle T, Dunn J, Flynn CR. Lipoprotein Profiles in Class III Obese Caucasian and African American Women with Nonalcoholic Fatty Liver Disease. PLoS One.2015 Nov 23;10(11):e0142676. doi: 10.1371/journal.pone.0142676
  12. Sharifnia T, Antoun J, Suarez G, Wattacheril J, Wilson K, Peek RM, Abumrad N, and Flynn CF. Hepatic TLR4 Signaling in Obese NAFLD. Am J Physiol Gastrointest Liver Physiol. 2015 Aug 15;309(4):G270-8. doi: 10.1152/ajpgi.00304.2014